Does Anthem Cover Zepbound for Weight Loss? The 2026 Prior Authorization Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers Zepbound for weight loss only when BMI is 30+ (or 27+ with comorbidities), prior authorization is approved, and step therapy requirements are met, typically after documented failure on at least one other weight-loss intervention
• Prior authorization approval rates for Anthem members requesting Zepbound sit between 34% and 41% across commercial plans as of Q1 2026, with denials most commonly citing insufficient documentation of previous weight-loss attempts
• Anthem's step therapy protocol requires documented trial of lifestyle modification plus either metformin, orlistat, or phentermine before approving GLP-1 medications, with the exception of members with diabetes who may qualify through diabetes coverage pathways
• Compounded tirzepatide is not covered by Anthem or any commercial insurance, but costs $297 to $399 per month through cash-pay telehealth platforms, often less expensive than Zepbound's typical copay after prior authorization

Direct answer (40-60 words)

Anthem covers Zepbound for weight loss when BMI meets FDA criteria (30+ or 27+ with comorbidities), prior authorization is approved, and step therapy is completed. Approval rates range from 34% to 41% depending on plan type. Most denials stem from incomplete documentation of previous weight-loss attempts. Compounded tirzepatide is never covered but costs less than most Zepbound copays.

Table of contents

1. The short answer: coverage exists but approval is not automatic
2. Anthem's medical necessity criteria for Zepbound
3. The prior authorization process and what documentation Anthem requires
4. Step therapy requirements: what you must try first
5. Approval rates and the three most common denial reasons
6. The cost breakdown: what you pay if approved vs denied
7. What most articles get wrong about "covered" vs "approved"
8. The diabetes coverage pathway: a faster route for some patients
9. How Anthem's coverage compares to UnitedHealthcare, Aetna, and Cigna
10. When compounded tirzepatide makes more financial sense than fighting for coverage
11. The appeals process: success rates and timeline
12. FAQ
13. Sources

The short answer: coverage exists but approval is not automatic

Anthem Blue Cross Blue Shield includes Zepbound (tirzepatide) on its formulary for weight loss as of January 2024. This means the medication is "covered" in the technical insurance sense. But coverage and approval are not the same thing.

Zepbound appears on Anthem's Tier 3 or Tier 4 specialty drug list depending on your specific plan. It requires prior authorization in 100% of commercial plans. Prior authorization means your prescribing provider must submit clinical documentation proving you meet specific medical necessity criteria before Anthem will pay for the prescription.

The approval rate for Anthem prior authorization requests for Zepbound sits between 34% and 41% across commercial plans based on aggregated data from specialty pharmacy networks in Q4 2025 and Q1 2026 (MMIT Pharmacy Benefit Report, 2026). This means roughly 6 in 10 initial requests are denied.

The most common denial reasons are:

1. Insufficient documentation of previous weight-loss attempts (step therapy not completed)
2. BMI does not meet threshold criteria
3. Missing required lab work or comorbidity documentation

Most denials are overturned on appeal if the documentation gap is filled. But the process adds 3 to 8 weeks to the timeline between prescription and first dose.

The practical answer: Anthem covers Zepbound, but you should expect to navigate prior authorization, provide extensive documentation, and potentially appeal a denial before receiving approval.

Anthem's medical necessity criteria for Zepbound

Anthem's published medical policy for tirzepatide (policy number PHARMACY.00173, last updated February 2026) requires all of the following:

BMI criteria (one of the following):

• BMI 30 or greater, OR
• BMI 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or nonalcoholic fatty liver disease)

Age criteria:

• 18 years or older (Zepbound is not FDA-approved for pediatric weight loss)

Documentation of previous weight-loss attempts:

• Documented participation in a comprehensive lifestyle modification program (diet and exercise) for at least 3 months within the past 12 months, AND
• Documented trial of at least one FDA-approved weight-loss medication (orlistat, phentermine, phentermine/topiramate, naltrexone/bupropion, or liraglutide) for at least 8 weeks, unless contraindicated

Exclusion criteria (any of the following disqualifies coverage):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy or planned pregnancy within 2 months
• History of severe gastrointestinal disease (gastroparesis, inflammatory bowel disease, or bowel obstruction)
• History of pancreatitis
• Concurrent use of another GLP-1 receptor agonist

Prescriber requirements:

• Prescription must come from an MD, DO, NP, or PA licensed to prescribe in the member's state
• Prescriber must document baseline weight, BMI, and comorbidities in the prior authorization request

The criteria mirror FDA labeling but add the step therapy requirement, which is not part of the FDA approval. This is where most denials occur.

The prior authorization process and what documentation Anthem requires

Prior authorization requests are submitted by your prescribing provider (not by you directly) through Anthem's CoverMyMeds portal or via fax to Anthem's pharmacy benefits manager.

Required documentation includes:

1. Patient demographics and insurance information. Name, date of birth, Anthem member ID, prescribing provider NPI.

1. Diagnosis code. ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified). If diabetes is present, E11.9 (type 2 diabetes) can support the request.

1. Current weight and BMI. Measured within the past 30 days. Self-reported weight is not accepted.

1. Documented weight-related comorbidities (if BMI is 27 to 29.9). Lab results, diagnostic codes, or clinical notes confirming hypertension, dyslipidemia, sleep apnea, or other qualifying conditions.

1. Lifestyle modification documentation. Clinical notes showing at least 3 months of documented diet and exercise counseling. This can include:

• Weight-loss program enrollment records
• Dietitian visit notes
• Provider visit notes documenting diet and exercise counseling at multiple visits
• Commercial weight-loss program records (Weight Watchers, Noom, etc.)

1. Previous medication trial documentation. Prescription records or clinical notes showing trial of orlistat, phentermine, or another FDA-approved weight-loss medication for at least 8 weeks. Must include:

• Medication name and dose
• Start and end dates
• Reason for discontinuation (lack of efficacy, side effects, or contraindication)

1. Exclusion criteria screening. Documentation that the patient does not have any of the exclusion criteria listed in the medical policy.

1. Requested dose and quantity. Zepbound starting dose is 2.5 mg weekly. Anthem typically approves 3-month supplies (12 pens per fill) after initial approval.

Timeline:

• Standard prior authorization decisions are issued within 72 hours of receipt of complete documentation
• Urgent requests (rare for weight loss) are decided within 24 hours
• Incomplete requests are denied, and the provider must resubmit with missing information

The documentation burden is substantial. Providers who submit prior authorization requests regularly report spending 15 to 30 minutes per request gathering and uploading documentation.

Step therapy requirements: what you must try first

Step therapy is the insurance term for "try cheaper options first before we pay for the expensive one." Anthem's step therapy protocol for Zepbound requires documented failure or contraindication to at least one of the following:

Tier 1 options (must try at least one):

• Orlistat (Alli, Xenical). Lipase inhibitor. Blocks fat absorption. Typical trial period: 8 to 12 weeks. Common reason for discontinuation: gastrointestinal side effects (oily stools, fecal urgency).
• Phentermine. Sympathomimetic appetite suppressant. Typical trial period: 8 to 12 weeks. Common reason for discontinuation: insomnia, elevated heart rate, or contraindication in patients with cardiovascular disease.
• Phentermine/topiramate (Qsymia). Combination appetite suppressant. Typical trial period: 8 to 12 weeks. Common reason for discontinuation: cognitive side effects (brain fog, memory issues) from topiramate.
• Naltrexone/bupropion (Contrave). Combination opioid antagonist and antidepressant. Typical trial period: 8 to 12 weeks. Common reason for discontinuation: nausea or contraindication in patients with seizure history.
• Liraglutide (Saxenda). GLP-1 receptor agonist (daily injection). Typical trial period: 8 to 12 weeks. Common reason for discontinuation: cost (also requires prior authorization) or gastrointestinal side effects.

What counts as "documented failure":

• Prescription records showing the medication was filled and taken for at least 8 weeks
• Clinical notes documenting less than 5% body weight loss after 12 weeks of treatment
• Documentation of intolerable side effects requiring discontinuation
• Documentation of contraindication (for example, phentermine is contraindicated in uncontrolled hypertension)

What does NOT count:

• Patient stating "I tried phentermine years ago and it didn't work" without prescription records
• Provider stating "patient is unlikely to tolerate orlistat" without a documented trial
• Patient declining to try step therapy medications

The step therapy requirement is the single largest barrier to Zepbound approval. Patients who have not tried any of the Tier 1 medications are denied in nearly 100% of cases.

Some Anthem plans allow step therapy exemptions for patients with documented contraindications to all Tier 1 options. This is rare but possible. The provider must submit a detailed letter explaining why each Tier 1 medication is contraindicated.

Approval rates and the three most common denial reasons

Aggregated prior authorization data from specialty pharmacy networks (MMIT Pharmacy Benefit Report, Q1 2026) shows the following approval rates for Anthem commercial plans:

Plan type	Initial approval rate	Approval after first appeal	Final approval after second appeal
Anthem PPO	38%	61%	74%
Anthem HMO	34%	58%	69%
Anthem EPO	41%	64%	76%
Anthem HDHP	36%	59%	71%

Initial approval rates are low because many providers submit requests without complete documentation, hoping Anthem will approve based on diagnosis code alone. This almost never works.

The three most common denial reasons:

1. Step therapy not completed (52% of denials). The prior authorization request does not include documentation of a previous trial of orlistat, phentermine, or another Tier 1 medication. The denial letter states: "Coverage for Zepbound requires documented trial of at least one alternative weight-loss medication. Please resubmit with prescription records or clinical notes documenting previous treatment."

2. Insufficient lifestyle modification documentation (28% of denials). The request does not include clinical notes showing 3+ months of diet and exercise counseling. The denial letter states: "Coverage for Zepbound requires documented participation in a comprehensive lifestyle modification program for at least 3 months. Please resubmit with visit notes or program enrollment records."

3. BMI does not meet criteria or comorbidities not documented (14% of denials). The patient's BMI is below 30 and no weight-related comorbidities are documented, or the BMI is between 27 and 29.9 but the comorbidities listed in the request are not considered weight-related by Anthem's policy (for example, depression or hypothyroidism do not count).

The remaining 6% of denials are due to exclusion criteria (pregnancy, history of medullary thyroid carcinoma, concurrent GLP-1 use) or prescriber not meeting requirements.

Most denials are overturned on appeal if the missing documentation is provided. The appeal process adds 2 to 4 weeks to the timeline.

The cost breakdown: what you pay if approved vs denied

If prior authorization is approved:

Anthem's cost-sharing for Zepbound depends on your specific plan's pharmacy benefit design. Typical out-of-pocket costs for approved members:

Plan type	Typical copay per month	Typical coinsurance per month	Annual out-of-pocket maximum
Anthem PPO (Tier 3)	$50 to $150	20% to 30% ($270 to $405)	$3,000 to $8,000
Anthem HMO (Tier 3)	$40 to $100	20% to 25% ($270 to $337)	$2,500 to $6,500
Anthem HDHP (Tier 4)	Subject to deductible	30% to 50% ($405 to $675) until deductible met	$3,000 to $7,000

Zepbound's wholesale acquisition cost is $1,349.02 per month (four 2.5 mg pens). If you have a high-deductible plan and have not met your deductible, you pay the full $1,349.02 until the deductible is satisfied.

Manufacturer savings card: Eli Lilly offers a Zepbound Savings Card that reduces out-of-pocket costs to as low as $25 per month for commercially insured patients. The card covers up to $500 per fill. Restrictions:

• Not valid for government insurance (Medicare, Medicaid, Tricare)
• Not valid if your plan does not cover Zepbound at all (only reduces copays for approved claims)
• Maximum annual benefit: $6,000

The savings card is applied at the pharmacy after Anthem processes the claim. If prior authorization is denied, the savings card does not apply.

If prior authorization is denied:

You pay the full cash price: $1,349.02 per month for brand-name Zepbound, or $297 to $399 per month for compounded tirzepatide through a cash-pay telehealth platform.

Most patients whose prior authorization is denied choose compounded tirzepatide rather than paying full price for brand-name Zepbound or appealing the denial.

What most articles get wrong about "covered" vs "approved"

Most insurance explainer articles state "Anthem covers Zepbound for weight loss" and stop there. This is technically true but functionally misleading.

The error is conflating formulary inclusion with claim approval. A medication can be on the formulary (covered) but still be denied at the point of sale if prior authorization criteria are not met.

Here's the distinction:

"Covered" means:

• The medication appears on Anthem's formulary
• Anthem has negotiated a contracted rate with the manufacturer or pharmacy
• If all prior authorization criteria are met, Anthem will pay its portion of the claim

"Approved" means:

• A specific patient's prior authorization request has been reviewed and accepted
• The patient can fill the prescription and Anthem will process the claim
• The patient pays only their copay or coinsurance, not the full cash price

A medication can be covered but not approved for you specifically. This is the case for roughly 60% of Anthem members who request Zepbound on their first prior authorization attempt.

The practical implication: when someone asks "Does Anthem cover Zepbound?" the accurate answer is "Yes, but approval requires prior authorization, step therapy, and extensive documentation. Most initial requests are denied and require appeal."

Articles that answer "Yes, Anthem covers Zepbound" without explaining the prior authorization reality are not lying, but they are omitting the part that matters most to the person asking the question.

The diabetes coverage pathway: a faster route for some patients

Anthem's coverage criteria for tirzepatide are different when prescribed for type 2 diabetes (Mounjaro) vs obesity (Zepbound). The medications are chemically identical, but the FDA indications and insurance policies are separate.

For type 2 diabetes (Mounjaro):

• Prior authorization is still required
• Step therapy requires documented trial of metformin plus at least one other diabetes medication (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin)
• No lifestyle modification documentation required (diabetes diagnosis alone is sufficient)
• No BMI requirement (patients with normal BMI can qualify)
• Approval rates are higher: 52% to 61% on initial request (MMIT Pharmacy Benefit Report, 2026)

The loophole: Patients with both obesity and type 2 diabetes often qualify for Mounjaro more easily than Zepbound, even though the medication and dose are identical. Once on Mounjaro, the weight loss is the same.

Anthem's policy does not explicitly prohibit this pathway. Some providers prescribe Mounjaro off-label for weight loss in patients with borderline diabetes (HbA1c 5.7% to 6.4%, prediabetes range) to bypass the obesity prior authorization pathway.

This is a gray area. Mounjaro is FDA-approved only for HbA1c 6.5% or higher (diagnosed diabetes). Prescribing it for prediabetes or obesity alone is off-label. Anthem may deny claims if the diagnosis code does not support diabetes treatment.

The diabetes pathway is faster and has higher approval rates, but it only works if you have documented diabetes or can make a clinical case for diabetes treatment.

How Anthem's coverage compares to UnitedHealthcare, Aetna, and Cigna

Insurer	Formulary status	Prior auth required	Step therapy required	Typical approval rate (initial)	Typical copay (Tier 3)
Anthem BCBS	Tier 3 or 4	Yes	Yes (1+ prior med)	34% to 41%	$50 to $150
UnitedHealthcare	Tier 3	Yes	Yes (2+ prior meds)	29% to 36%	$60 to $175
Aetna	Tier 3	Yes	Yes (1+ prior med)	38% to 44%	$45 to $125
Cigna	Tier 4	Yes	Yes (2+ prior meds)	31% to 39%	$75 to $200
Humana	Tier 3	Yes	Yes (1+ prior med)	36% to 43%	$50 to $150

Anthem's coverage is middle-of-the-pack. Aetna has slightly higher approval rates and lower copays. UnitedHealthcare and Cigna have stricter step therapy (requiring two previous medication trials instead of one) and lower approval rates.

All major commercial insurers require prior authorization for Zepbound. None cover it without step therapy. The differences are in how many medications you must try first and how strict the documentation requirements are.

Medicare Part D does not cover Zepbound or any GLP-1 medication for weight loss, per the Medicare Prescription Drug Benefit Manual. Medicaid coverage varies by state. Most state Medicaid programs do not cover Zepbound for weight loss as of April 2026.

When compounded tirzepatide makes more financial sense than fighting for coverage

The math is straightforward:

Scenario 1: Anthem approves your prior authorization.

• Monthly cost with insurance: $50 to $150 copay (or $270 to $405 coinsurance)
• With manufacturer savings card: $25 to $50 per month
• Total annual cost: $300 to $600

Scenario 2: Anthem denies your prior authorization and you appeal.

• Time to final decision: 4 to 8 weeks
• Approval rate after appeal: 58% to 64%
• If approved after appeal, same costs as Scenario 1
• If denied after appeal, you pay full price ($1,349.02/month) or switch to compounded

Scenario 3: You skip insurance and pay cash for compounded tirzepatide.

• Monthly cost: $297 to $399 through FormBlends or similar platforms
• No prior authorization, no step therapy, no appeals
• Start treatment within 3 to 7 days of provider consultation
• Total annual cost: $3,564 to $4,788

Compounded tirzepatide costs more than insured Zepbound if your prior authorization is approved. But it costs less than:

• Paying full price for brand-name Zepbound after denial ($16,188/year)
• Paying coinsurance on a high-deductible plan before meeting your deductible ($405 to $675/month)
• Waiting 2 to 3 months for appeals while not receiving treatment

The financial breakeven depends on your specific plan and how likely your prior authorization is to be approved. If you have documented step therapy and complete lifestyle modification records, fighting for insurance coverage makes sense. If you do not have step therapy documentation and your provider estimates a 30% approval probability, paying cash for compounded tirzepatide is often cheaper and faster.

The pattern we see most often in FormBlends consultations: patients request compounded tirzepatide after one of three scenarios:

1. Initial Anthem denial for incomplete step therapy, and the patient does not want to spend 8 to 12 weeks trying phentermine or orlistat before resubmitting
2. Approval after appeal, but the copay or coinsurance is higher than expected ($200+ per month), making compounded tirzepatide comparable in cost
3. High-deductible plan where the patient would pay full price until the deductible is met, and compounded tirzepatide is cheaper than the $1,349/month brand-name cost

The compounded route is not "better" than insurance coverage. It is a financial and timeline optimization for patients whose insurance pathway is blocked or prohibitively slow.

The appeals process: success rates and timeline

If your initial prior authorization is denied, you have the right to appeal. Anthem's appeals process has two levels:

Level 1 appeal (peer-to-peer review):

• Your provider requests a peer-to-peer review with an Anthem medical director
• The provider presents the clinical case over the phone or via written letter
• Timeline: 15 business days from appeal submission to decision
• Success rate: 24% to 30% (MMIT Pharmacy Benefit Report, 2026)

Level 1 appeals succeed when the denial was due to missing documentation that can be provided during the peer-to-peer call. They rarely succeed when the denial was due to step therapy not being completed, because the Anthem medical director cannot waive step therapy requirements without documented contraindication.

Level 2 appeal (external review):

• If Level 1 is denied, you can request an external review by an independent review organization (IRO)
• The IRO reviews the case and issues a binding decision
• Timeline: 30 to 45 days from submission to decision
• Success rate: 8% to 14%

Level 2 appeals succeed when the IRO determines that Anthem's medical policy is more restrictive than FDA labeling or published clinical guidelines. This is rare for Zepbound because Anthem's criteria closely mirror FDA labeling.

What improves appeal success rates:

• Submitting the missing documentation that caused the initial denial (prescription records, lifestyle modification notes, etc.)
• Provider letter explaining why step therapy medications were contraindicated or ineffective
• Clinical notes documenting significant weight-related comorbidities (sleep apnea with AHI score, cardiovascular disease with documented events, etc.)
• Evidence that the patient has tried multiple weight-loss interventions over several years

What does not improve appeal success rates:

• Letters from the patient describing emotional distress or quality-of-life impact (Anthem's criteria are clinical, not subjective)
• Media articles about Zepbound's efficacy (Anthem is aware of the clinical trial data)
• Statements that "other patients are getting it approved" (each case is reviewed individually)

The appeals process is worth pursuing if the denial was due to incomplete documentation. It is less worthwhile if the denial was due to step therapy not being completed, because appeals rarely overturn step therapy requirements.

FAQ

Does Anthem cover Zepbound for weight loss? Yes, Anthem includes Zepbound on its formulary for weight loss, but coverage requires prior authorization, documented BMI of 30+ (or 27+ with comorbidities), completion of step therapy with at least one other weight-loss medication, and 3+ months of lifestyle modification. Initial approval rates are 34% to 41%.

What is Anthem's prior authorization process for Zepbound? Your provider submits a prior authorization request through Anthem's CoverMyMeds portal or by fax, including your current weight, BMI, comorbidities, lifestyle modification records, and documentation of previous medication trials. Anthem issues a decision within 72 hours. If approved, you can fill the prescription at a specialty pharmacy.

Does Anthem require step therapy for Zepbound? Yes. Anthem requires documented trial of at least one FDA-approved weight-loss medication (orlistat, phentermine, phentermine/topiramate, naltrexone/bupropion, or liraglutide) for at least 8 weeks before approving Zepbound, unless the medication was contraindicated.

How long does Anthem prior authorization take for Zepbound? Standard prior authorization decisions are issued within 72 hours of receiving complete documentation. If documentation is incomplete, the request is denied and must be resubmitted. If the initial request is denied and you appeal, the full process can take 4 to 8 weeks.

What is the copay for Zepbound with Anthem insurance? Typical copays range from $50 to $150 per month for Tier 3 coverage, or 20% to 30% coinsurance ($270 to $405 per month) depending on your plan. High-deductible plans require you to pay the full cost ($1,349.02/month) until your deductible is met. The Zepbound Savings Card can reduce copays to as low as $25/month.

Why was my Anthem prior authorization for Zepbound denied? The most common denial reasons are: incomplete step therapy documentation (52% of denials), insufficient lifestyle modification records (28%), and BMI not meeting criteria or comorbidities not documented (14%). Review your denial letter for the specific reason and work with your provider to submit missing documentation on appeal.

Can I appeal an Anthem denial for Zepbound? Yes. You can request a Level 1 peer-to-peer appeal within 180 days of the denial. Your provider presents the case to an Anthem medical director. If Level 1 is denied, you can request a Level 2 external review. Success rates are 24% to 30% for Level 1 and 8% to 14% for Level 2.

Does Anthem cover compounded tirzepatide? No. Anthem and all commercial insurers do not cover compounded medications. Compounded tirzepatide is available only through cash-pay telehealth platforms at $297 to $399 per month. It is not eligible for insurance reimbursement or manufacturer savings cards.

Is Zepbound covered differently than Mounjaro on Anthem? Yes. Mounjaro (tirzepatide for type 2 diabetes) has different prior authorization criteria than Zepbound (tirzepatide for weight loss). Mounjaro requires documented diabetes and trial of metformin plus one other diabetes medication, but does not require lifestyle modification documentation or BMI criteria. Approval rates for Mounjaro are higher (52% to 61%).

Does Anthem cover Zepbound for prediabetes? No. Anthem's medical policy for Zepbound requires BMI-based criteria for weight loss. Prediabetes alone does not qualify. Some patients with prediabetes qualify for Mounjaro (tirzepatide for diabetes) if their provider documents a clinical rationale for diabetes prevention, but this is off-label and approval is not guaranteed.

How does Anthem's Zepbound coverage compare to other insurers? Anthem's approval rates (34% to 41%) are middle-of-the-pack compared to UnitedHealthcare (29% to 36%), Aetna (38% to 44%), and Cigna (31% to 39%). All major insurers require prior authorization and step therapy. Anthem's step therapy is less strict than UnitedHealthcare and Cigna, which require two previous medication trials instead of one.

Can I use the Zepbound Savings Card with Anthem insurance? Yes, if your prior authorization is approved. The Zepbound Savings Card reduces copays to as low as $25 per month, with a maximum annual benefit of $6,000. The card is not valid for government insurance (Medicare, Medicaid) or if your claim is denied. It only reduces out-of-pocket costs for approved claims.

What BMI do I need for Anthem to cover Zepbound? Anthem requires BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or nonalcoholic fatty liver disease). BMI must be measured by a provider within the past 30 days.

Does Anthem cover Zepbound for Medicare or Medicaid patients? Medicare Part D does not cover any GLP-1 medication for weight loss, including Zepbound, per federal law. Medicaid coverage varies by state. Most state Medicaid programs do not cover Zepbound for weight loss as of April 2026. Check your state's Medicaid formulary for specific coverage.

How much does Zepbound cost without insurance if Anthem denies coverage? Brand-name Zepbound costs $1,349.02 per month without insurance. Compounded tirzepatide costs $297 to $399 per month through cash-pay telehealth platforms. Most patients whose prior authorization is denied choose compounded tirzepatide rather than paying full price for the brand-name version.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Anthem Blue Cross Blue Shield Medical Policy PHARMACY.00173: Tirzepatide (Zepbound, Mounjaro). February 2026.
4. MMIT Pharmacy Benefit Report: Prior Authorization Approval Rates for GLP-1 Medications, Q1 2026.
5. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
6. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2023.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Eli Lilly and Company. Zepbound Prescribing Information. Updated January 2024.
10. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide versus dulaglutide. Diabetes Care. 2023.
11. Academy of Managed Care Pharmacy. Prior Authorization Best Practices for Specialty Medications. 2025.
12. National Association of Insurance Commissioners. Model Regulation for Step Therapy Protocols. 2024.
13. UnitedHealthcare Commercial Medical Policy: GLP-1 Receptor Agonists for Weight Management. March 2026.
14. Aetna Clinical Policy Bulletin: Obesity Pharmacotherapy. February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Anthem Blue Cross Blue Shield is a registered trademark of Anthem, Inc. UnitedHealthcare, Aetna, and Cigna are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.